Publicacións nas que colabora con Marta Alvarez Estevez (12)

2021

  1. Mural Endocarditis: The GAMES Registry Series and Review of the Literature

    Infectious Diseases and Therapy, Vol. 10, Núm. 4, pp. 2749-2764

2020

  1. A Contemporary Picture of Enterococcal Endocarditis

    Journal of the American College of Cardiology, Vol. 75, Núm. 5, pp. 482-494

  2. GEHEP 010 study: Prevalence and distribution of hepatitis B virus genotypes in Spain (2000–2016)

    Journal of Infection, Vol. 81, Núm. 4, pp. 600-606

  3. The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations

    The Journal of antimicrobial chemotherapy, Vol. 75, Núm. 5, pp. 1294-1300

2019

  1. Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice

    The Journal of antimicrobial chemotherapy, Vol. 74, Núm. 6, pp. 1693-1700

2018

  1. Continued propagation of the CRF19_cpx variant among HIV-positive MSM patients in Spain

    Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 4, pp. 1031-1038

2016

  1. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe

    Clinical Infectious Diseases, Vol. 62, Núm. 5, pp. 655-663

  2. Using NS5B sequencing for hepatitis C virus genotyping reveals discordances with commercial platforms

    PLoS ONE, Vol. 11, Núm. 4

2015

  1. Procedimientos en Microbiología Clínica (número 6b, 2.a edición 2014)

    Enfermedades Infecciosas y Microbiologia Clinica Monografias

2014

  1. Clinically relevant transmitted drug resistance to first line antiretroviral drugs and implications for recommendations

    PLoS ONE, Vol. 9, Núm. 3

2013

  1. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

    AIDS, Vol. 27, Núm. 1, pp. 81-85

2012

  1. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

    Retrovirology, Vol. 9